Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand ...
Read moreNovo Nordisk announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand ...
Read moreHeartseed Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive worldwide ...
Read moreNovo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US ...
Read moreNovo Nordisk today presented results from RESCUE, a phase 2 randomised, double-blind, placebo controlled clinical trial ...
Read moreNovo Nordisk announced the decision to enter phase 3a development in obesity with oral semaglutide 50 ...
Read moreNovo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the ...
Read moreNovo Nordisk today announced new results from the STEP phase 3a clinical trial programme demonstrated weight ...
Read moreNovo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Refusal ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.